

# ISO 14155:2011-02 (E)

## Clinical investigation of medical devices for human subjects - Good clinical practice

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>1</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>2</b>
<b>4</b>	<b>Ethical considerations .....</b>	<b>7</b>
4.1	General .....	7
4.2	Improper influence or inducement .....	8
4.3	Compensation and additional health care .....	8
4.4	Responsibilities .....	8
4.5	Communication with the ethics committee (EC) .....	8
4.5.1	General .....	8
4.5.2	Initial EC submission .....	8
4.5.3	Information to be obtained from the EC .....	9
4.5.4	Continuing communication with the EC .....	9
4.5.5	Continuing information to be obtained from the EC .....	9
4.6	Vulnerable populations .....	9
4.7	Informed consent .....	10
4.7.1	General .....	10
4.7.2	Process of obtaining informed consent .....	10
4.7.3	Special circumstances for informed consent .....	10
4.7.4	Information to be provided to the subject .....	11
4.7.5	Informed consent signature .....	13
4.7.6	New information .....	13
<b>5</b>	<b>Clinical investigation planning .....</b>	<b>14</b>
5.1	General .....	14
5.2	Risk evaluation .....	14
5.3	Justification for the design of the clinical investigation .....	14
5.4	Clinical investigation plan (CIP) .....	14
5.5	Investigator's brochure (IB) .....	15
5.6	Case report forms (CRFs) .....	15
5.7	Monitoring plan .....	15
5.8	Investigation site selection .....	15
5.9	Agreement(s) .....	15
5.10	Labelling .....	15
5.11	Data monitoring committee (DMC) .....	16
<b>6</b>	<b>Clinical investigation conduct .....</b>	<b>16</b>
6.1	General .....	16
6.2	Investigation site initiation .....	16
6.3	Investigation site monitoring .....	16
6.4	Adverse events and device deficiencies .....	16
6.4.1	Adverse events .....	16
6.4.2	Device deficiencies .....	16
6.5	Clinical investigation documents and documentation .....	17
6.5.1	Amendments .....	17
6.5.2	Subject identification log .....	17
6.5.3	Source documents .....	17

6.6	Additional members of the investigation site team .....	17
6.7	Subject privacy and confidentiality of data .....	17
6.8	Document and data control .....	18
6.8.1	Traceability of documents and data .....	18
6.8.2	Recording of data .....	18
6.8.3	Electronic clinical data systems .....	18
6.9	Investigational device accountability .....	19
6.10	Accounting for subjects .....	19
6.11	Auditing .....	19
7	Suspension, termination and close-out of the clinical investigation .....	20
7.1	Suspension or premature termination of the clinical investigation .....	20
7.1.1	Procedure for suspension or premature termination .....	20
7.1.2	Procedure for resuming the clinical investigation after temporary suspension .....	21
7.2	Routine close-out .....	21
7.3	Clinical investigation report .....	21
7.4	Document retention .....	22
8	Responsibilities of the sponsor .....	22
8.1	Clinical quality assurance and quality control .....	22
8.2	Clinical investigation planning and conduct .....	23
8.2.1	Selection of clinical personnel .....	23
8.2.2	Preparation of documents and materials .....	23
8.2.3	Conduct of clinical investigation .....	24
8.2.4	Monitoring .....	24
8.2.5	Safety evaluation and reporting .....	27
8.2.6	Clinical investigation close-out .....	27
8.3	Outsourcing of duties and functions .....	28
8.4	Communication with regulatory authorities .....	28
9	Responsibilities of the principal investigator .....	28
9.1	General .....	28
9.2	Qualification of the principal investigator .....	28
9.3	Qualification of investigation site .....	29
9.4	Communication with the EC .....	29
9.5	Informed consent process .....	29
9.6	Compliance with the CIP .....	29
9.7	Medical care of subjects .....	30
9.8	Safety reporting .....	31
	Annex A (normative) Clinical investigation plan (CIP) .....	32
	Annex B (normative) Investigator's brochure (IB) .....	39
	Annex C (informative) Case report forms (CRFs) .....	41
	Annex D (informative) Clinical investigation report .....	43
	Annex E (informative) Essential clinical investigation documents .....	48
	Annex F (informative) Adverse event categorization .....	55
	Bibliography .....	58